GleamWall
中文EN

ACRV Acrivon Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1781174 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY14.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-74.1%
ROA-64.0%
ROIC (approx.)-104.8%
Asset turnover—

Leverage & solvency

Liabilities / assets17.5%
Debt / equity0.00x
Current ratio5.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$59.99M$63.99M
SG&A expense$24.12M$25.21M
Operating income-$84.11M-$89.20M
Pretax income-$77.83M-$80.44M
Income tax$0—
Net income-$77.91M-$80.56M
EBITDA-$82.76M-$88.19M
EPS (basic)-2.02-2.38
EPS (diluted)-2.02-2.38
Weighted avg. shares (diluted)38.51M33.79M
Balance sheet
Cash & equivalents$41.50M$39.82M
Short-term investments$77.08M$139.66M
Current assets$120.44M$181.63M
PP&E, net$4.89M$4.47M
Total assets$129.72M$196.59M
Current liabilities$15.66M$17.21M
Total liabilities$17.20M$19.80M
Shareholders' equity$112.52M$176.79M
Shares outstanding31.65M31.23M
Cash flow statement
Operating cash flow-$63.66M-$65.67M
Capital expenditure$1.67M$2.77M
Free cash flow-$65.33M-$68.44M
Investing cash flow$66.10M-$51.77M
Financing cash flow-$749,000$121.03M
Depreciation & amortization$1.36M$1.01M
Stock-based compensation$14.72M$14.29M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.